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The altered form of the high-mobility group A2 (HMGA2) gene is somehow related to the generation of human benign and
malignant tumours of mesenchymal origin. However, only a few data on the expression of HMGA2 in malignant tumour originating
from epithelial tissue are available. In this study, we examined the HMGA2 expression level in pancreatic carcinoma, and investigated
whether alterations in the HMGA2 expression level are associated with a malignant phenotype in pancreatic tissue. High-mobility
group A2 mRNA and protein expression was determined in eight surgically resected specimens of non-neoplastic tissue (six
specimens of normal pancreatic tissue and two of chronic pancreatitis tissue) and 27 pancreatic carcinomas by highly sensitive reverse
transcriptase–polymerase chain reaction (RT–PCR) techniques and immunohistochemical staining, respectively. Reverse
transcriptase–polymerase chain reaction analysis revealed the expression of the HMGA2 gene in non-neoplastic pancreatic tissue,
although its expression level was significantly lower than that in carcinoma. Immunohistochemical analysis indicated that the presence
of the HMGA2 gene in non-neoplastic pancreatic tissue observed in RT–PCR reflects its abundant expression in islet cells, together
with its focal expression in duct epithelial cells. Intense and multifocal or diffuse HMGA2 immunoreactivity was noted in all the
pancreatic carcinoma examined. A strong correlation between HMGA2 overexpression and the diagnosis of carcinoma was
statistically verified. Based on these findings, we propose that an increased expression level of the HMGA2 protein is closely
associated with the malignant phenotype in the pancreatic exocrine system, and accordingly, HMGA2 could serve as a potential
diagnostic molecular marker for distinguishing pancreatic malignant cells from non-neoplastic pancreatic exocrine cells.
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The high-mobility group A (HMGA) family of proteins in
mammals is composed of four proteins: HMGA1a, HMGA1b,
HMGA1c, and HMGA2. The former three proteins are encoded by
a single functional gene, that is, HMGA1 (formerly HMGI(Y)),
while the last one is a product of a separate gene, that is, HMGA2
(formerly HMGI-C) (Manfioletti et al, 1991; Johnson et al, 1998).
High-mobility group A2 has an approximately 50% amino-acid
sequence homology with HMGA1, and features an internal 11
amino-acid deletion that characterises HMGA1 (Manfioletti et al,
1991; Tallini and Dal Cin, 1999). High-mobility group A2 proteins
bind to the minor groove of AT-rich DNA sequences, thereby
inducing a bend within the DNA (Thanos and Maniatis, 1992).
They cannot initiate transcription, but they can enhance promotor
binding of transcription factors (Thanos and Maniatis, 1992;
Grosschedl et al, 1994; Mantovani et al, 1998).
High-mobility group A2 has been shown to be expressed
abundantly during embryogenesis, but its expression is either
undetectable or remains at low levels in other normal adult tissues
(Manfioletti et al, 1991; Zhou et al, 1995; Rogalla et al, 1996;
Rommel et al, 1997; Hirning-Folz et al, 1998), suggesting that
HMGA2 plays an important role (or roles) in cell proliferation and/
or differentiation. Consistent with this, it has been demonstrated
that HMGA proteins are phosphorylated in a cell-cycle-dependent
manner (Reeves et al, 1991). Functionally, knocking out the
HMGA2 gene in mice leads to the pygmy phenotype with
characteristic hypoplasia of mesenchymal tissue, thereby confirm-
ing the important role(s) of HMGA2 in mammalian growth and
development (Zhou et al, 1995).
The altered form of the HMGA2 gene, on the other hand, could
somehow be related to the generation of human benign and
malignant tumours. Rearrangements of the HMGA2 gene, for
example, have been frequently observed in benign tumours of
mesenchymal origin (Ashar et al, 1995; Schoenmarkers et al, 1995).
In such cases, the gene rearrangements were the consequence of
chromosomal translocation involving regions 12q13–15, where the
HMGA2 gene is located. The HMGA2 modifications consist of the
loss of the carboxyl-terminal tail and its fusion with ectopic
sequences (Ashar et al, 1995; Schoenmarkers et al, 1995). The
truncation of HMGA2, rather than its fusion with other genes, has
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yalso been shown to be responsible for cell transformation (Fedele
et al, 1998). This was confirmed in transgenic mice carrying a
truncated HMGA2, which developed a giant phenotype together
with a marked expansion of the retroperitoneal and subcutaneous
white adipose tissues (Battista et al, 1999; Arlotta et al, 2000).
Interestingly, most of these tumours related to the alteration in
HMGA2 are of nonepithelial origin. In contrast, only a few data on
the expression of HMGA2 in human malignant tumour originating
from epithelial tissue are available (Rogalla et al, 1997). The
overexpression of HMGA2 mRNA has been shown to be closely
associated with high histologic grade in breast cancer (Rogalla et al,
1997), suggesting that the expression level of the HMGA2 protein/
gene could be a potential clinicopathological marker with
prognostic implications for a wide range of cancers. To test this
possibility, we examined the HMGA2 expression in pancreatic
cancers in the present study, and investigated whether alterations
in HMGA2 are associated with the malignant phenotype of
tumours in pancreatic tissue. To this end, HMGA2 mRNA
expression was first analysed by highly sensitive reverse tran-
scriptase–polymerase chain reaction (RT–PCR) techniques. Im-
munohistochemical detection of HMGA2 protein using a specific
antibody was also attempted. Although relatively simple and easy
to perform, immunohistochemistry is a potential method of
examining whether the expression of a certain protein is specific
to tumour cells, because it allows precise correlation of the protein
expression with the phenotype of the cells on individual cell basis
(Abe et al, 2000). In this sense, immunohistochemistry can provide
more useful information than other assays by which proteins and/
or mRNAs are extracted from tumours; possibly including a
mixture of proteins from normal and irrelevant cells such as acinar
cells or islet cells of the pancreas in the analysis (Abe et al, 2000).
Based on the above considerations, we determined HMGA2
protein expression immunohistochemically on surgically resected
specimens, normal pancreatic tissue, chronic pancreatitis tissue,
and carcinomas of the pancreas.
MATERIALS AND METHODS
Tissue samples
The tissue samples were obtained at the time of surgery at the First
Department of Surgery, Kyorin University Hospital, between
October 1996 and August 2001. Specimens from 27 pancreatic
carcinomas (20 primary carcinomas, four liver metastases, two
peritoneal metastases, and one lymph node metastasis) and eight
non-neoplastic tissues (six normal pancreatic and two chronic
pancreatitis tissues) were obtained. In all, 27 carcinomas were
histologically diagnosed as 12 well-differentiated tubular adeno-
carcinomas, six moderately differentiated tubular adenocarcino-
mas, seven poorly differentiated tubular adenocarcinomas, and
two adenosquamous carcinomas (they were evaluated histologi-
cally according to the criteria of the Japan Pancreas Society).
Normal pancreatic tissues were obtained from either patients who
have undergone pancreatectomy due to pancreatic neoplasms or
those with gastric cancer who have undergone pancreatectomy for
lymph node dissection. In either case, specimens were obtained
from a macroscopically healthy region distinct from the neoplastic
lesion. All patients gave their informed consent prior to their
inclusion in the study. Among the samples, those from 17
pancreatic carcinomas and six non-neoplastic pancreatic tissues
were frozen on dry ice immediately after surgical resection for
molecular investigation (RT–PCR), and stored at  801C until use.
All the tissue specimens were fixed for immunohistochemical
analysis as soon as possible after surgical resection in 4%
paraformaldehyde in phosphate-buffered saline (PBS) at 41C for
14h, followed by cryoprotection in a graded concentration series
of sucrose in PBS. The specimens were then embedded in the OCT
compound, frozen, and stored at  801C until analysis. All the
tissue specimens were histologically examined and pathological
diagnoses were confirmed.
RT–PCR analysis
Reverse transcriptase–polymerase chain reaction for the HMGA2
expression was performed using a heminested PCR technique as
described previously (Rogalla et al, 1996; Rommel et al, 1997).
Total RNA was extracted by a modified guanidine thiocyanate
method as described previously (Miyatani et al, 1986). cDNA was
synthesised using the adapter primer (AP) AAG GAT CCG TCG
ACA TC (T)17 and Superscript II reverse transcriptase (Gibco
BRL, Gaithersburg, MD, USA). For the first and second rounds of
the heminested PCR, the same lower primer (Rev) 50-TCC TCC
TGA GCA GGC TTC-30 (exon 4/5) was used. The forward primer
50-CTT CAG CCC AGG GAC AAC-30 (exon 1) and the nested
primer 50-CAT CGC CTC AGA AGA GAG GAC-30 (exon 1) were
used as upper primers. The PCR amplifications were both
performed for 30 cycles (1min at 941C, 1min at 531C, and 2min
at 721C). As a control reaction for intact RNA and cDNA, PCR
amplification of the cDNA of the housekeeping gene b-actin was
performed for all samples to exclude false-negative PCR results.
Only those samples positive for b-actin were used for this study.
The resulting PCR products were clearly visualised by gel
electrophoresis on a 2% agarose-gel stained with ethidium
bromide as bands at 220 base pairs (bp) for HMGA2 and at
154bp for b-actin (Figure 1). The resulting bands were sequenced
and their sequences were found to be identical to that of HMGA2.
Immunohistochemical analysis
Immunohistochemical examinations were performed by the
avidin–biotin complex immunoperoxidase technique using an
Avidin-Biotinylated Enzyme Complex kit (Vector Laboratories,
Inc. CA, USA) as described previously (Abe et al, 1999, 2000, 2002).
The HMGA2 protein expression was immunohistochemically
analysed on surgically resected specimens, together with four
pancreatic cancer cell lines (PANC-I, MIA PaCa-2, BxPC-3, and
AsPc-1) using HMGA2-specific antibodies, raised in rabbit against
the recombinant HMGA2 protein (Berlingieri et al, 1995). In brief,
frozen sections 5 (5m thick) were prepared, transferred onto poly-
L-lysine-coated slides, air-dried, and then washed in PBS, followed
by quenching of endogeneous peroxidase activity with 0.3%
hydrogen peroxide in methanol. After further rinsing with PBS,
the sections were incubated with normal goat serum for 20min at
room temperature to block nonspecific binding, and then
incubated with the primary anti-HMGA2 antibody (1:100 dilu-
tion) 14h at 41C. After another wash in 0.2% Triton X in PBS, the
sections were further incubated with biotinylated anti-rabbit IgG
for 30min at room temperature, followed by washes in 0.2% Triton
X in PBS. After the addition of streptavidin–biotin-conjugated
peroxidase and incubation for 30min at room temperature, the
220bp
154bp
DL 1 2 3 4 5 6 7 8 9 10 11
HMGA2
β-actin
Figure 1 Reverse transcriptase–polymerase chain reaction products of
HMGA2 after gel electrophoresis and ethidium bromide staining. Results
show specific 220-bp bands. DL, DNA molecular weight marker; lane 1,
positive control (hepatoma cell line HEP3B, which is known to express high
level of HMGA2); lane 2, normal pancreas; lane 3, chronic pancreatitis; lane
4–11, pancreatic carcinomas.
HMGA2 expression in pancreatic carcinoma
N Abe et al
2105
British Journal of Cancer (2003) 89(11), 2104–2109 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
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localisation of the HMGA2 protein was visualised by incubating
the sections with 3,30-diaminobenzidine. The slides were counter-
stained with Mayer’s haematoxylin, dehydrated in a graded alcohol
series, cleared in xylene, and mounted. Negative control staining
was carried out by replacing the primary antibody with normal
rabbit serum under the same experimental conditions. The
immunostained slides were evaluated microscopically by a single
investigator (NA) according to the criteria published previously
(Abe et al, 1999, 2000) without prior knowledge of the clinical data
for each case. The percentage of HMGA2-positive cells was scored
by counting approximately 300–1000 tumour cells in three
randomly selected fields (Abe et al, 1999, 2000, 2002). The
immunohistochemical evaluation was considered positive when
the HMGA2 nuclear immunoreactivity was detected in more than
20% of the cells according to the criteria published previously (Abe
et al, 1999, 2000).
RESULTS
Expression of HMGA2 mRNA determined by RT–PCR
Among the six non-neoplastic tissue samples, five, including three
normal tissues and two chronic pancreatitis tissues, gave rise to
detectable HMGA2 bands, while one normal tissue sample showed
no detectable HMGA2 band. The signal intensities of the HMGA2
band in chronic pancreatitis tissue samples were almost equivalent
to those observed in the normal tissue samples. All the 17 samples
of pancreatic carcinomas also showed HMGA2 bands by RT–PCR
(Figure 1, Table 1). When the signal intensities of these HMGA2
bands were compared between non-neoplastic and carcinoma
samples, the latter showed at least several fold more intense band
than the former (Figure 1). Thus, an increased expression level of
the HMGA2 mRNA is a distinct feature of pancreatic carcinoma.
Expression of HMGA2 protein determined by
immunohistochemistry
To determine whether the altered HMGA2 mRNA expression
observed in pancreatic carcinoma is associated with alterations in
protein expression, we analysed the expression of the HMGA2
protein by immunohistochemistry. Its expression was first
analysed in four pancreatic cancer cell lines. Intense multifocal
or diffuse HMGA2 nuclear immunoreactivity was characteristically
observed in these cell lines (Figures 2A–D). In both normal
pancreas and chronic pancreatitis tissues, acinar cells did not
exhibit any detectable HMGA2 immunoreactivity; however, a small
proportion of duct epithelial cells showed faint HMGA2 immunor-
eactivity (Figure 3A). On the other hand, in the endocrine region,
islet cells showed intense and diffuse HMGA2 immunoreactivity
(Figures 3B and F). In these cells, although HMGA2 immunor-
eactivity was localised mainly in the nuclei, faint staining was also
observed within the cytoplasm. These results clearly indicated that
the presence of the HMGA2 gene in non-neoplastic pancreatic
tissue observed in the RT–PCR analysis reflects its expression in
islet cells, together with its focal expression in duct epithelial cells.
No significant difference in immunohistochemical findings was
found between normal tissues and chronic pancreatitis tissues.
When the expression of the HMGA2 protein in surgical specimens
of carcinomas was then analysed, multifocally or diffusely
distributed intense HMGA2 immunoreactivity was noted in all
the pancreatic carcinoma specimens examined (Figures 3C–F).
Intense nuclear staining was characteristically observed in the
carcinoma cells. High-mobility group A2-positive carcinoma cells
were observed regardless of the degree of differentiation (well/
moderately or poorly differentiated tubular adenocarcinoma),
histology type (tubular adenocarcinoma or adenosquamous
carcinoma), or tumour site (primary or metastatic site). A strong
correlation between HMGA2 overexpression and the diagnosis of
carcinoma was noted (Fisher’s exact probability, Po0.0001,
Table 1).
DISCUSSION
To evaluate the association between HMGA2 expression and the
pathological diagnosis of pancreatic carcinoma, we investigated
the expression of HMGA2 gene/protein in duct cell carcinoma and
non-neoplastic tissue of the pancreas. High-mobility group A2
expression has been shown to be undetectable or to remain at low
levels in normal adult tissues (Manfioletti et al, 1991; Zhou et al,
1995; Rogalla et al, 1996; Rommel et al, 1997; Hirning-Folz et al,
1998; Gattas et al, 1999). In the present study, however, a highly
sensitive RT–PCR analysis revealed the expression of the HMGA2
gene in non-neoplastic pancreatic tissue, although its expression
level was significantly lower than that in carcinoma. Immunohis-
tochemical analysis indicated that the presence of the HMGA2
gene in non-neoplastic pancreatic tissue observed in the RT–PCR
analysis reflects its abundant expression in islet cells together with
its focal expression in duct epithelial cells. Thus, this study showed
that the HMGA2 gene or protein is present even in normal
pancreatic tissue. In HMGA2 immunohistochemical analysis, while
only a small proportion of duct epithelial cells in the non-
neoplastic tissue specimens showed HMGA2 immunoreactivity, a
significantly higher proportion of carcinoma cells showed intense
staining. In fact, a strong correlation between HMGA2 over-
expression and the diagnosis of carcinoma was statistically
verified. These findings indicate that an increased expression level
of the HMGA2 protein is closely associated with the malignant
phenotype in the pancreatic exocrine system, and accordingly,
HMGA2 could serve as a potential diagnostic molecular marker for
distinguishing pancreatic malignant cells from non-neoplastic
pancreatic exocrine cells. A possible application of the results of
the present study would be the determination of the HMGA2 gene
and/or protein expression level in pancreatic juice collected at the
time of endoscopic retrograde pancreatography. Using a sensitive
and quantitative method such as competitive RT–PCR or
immunoassay, the detection of even a small number of cancer
cells could well be expected.
In order to evaluate the biological significance of the present
results, it would be essential to understand the mechanisms by
which the HMGA2 gene is involved in tumorigenesis, which
unfortunately remain largely unclear. A clue to this issue was,
however, provided by a recent report that transgenic mice carrying
the HMGA2 gene developed pituitary adenomas (Fedele et al,
2002). These findings indicate that the high HMGA2 expression
level has a critical role in neoplastic transformation of cells.
Another clue was also demonstrated when antisense HMGA2 RNA
Table 1 HMGA2 expression in pancreatic carcinoma
Histological type
of pancreatic
specimens
No. of positive
specimens/no.
of specimens
analysed by
RT–PCR
No. of positive
a
specimens/no.
of specimens analysed by
immunohistochemistry
Non-neoplastic tissue
Normal pancreas 3/4 (75%) 0/6 (0%)
Chronic pancreatitis 2/2 (100%) 0/2 (0%)
Duct cell carcinoma 17/17 (100%) 27/27 (100%)
aThe immunostained slides were scored as positive for immunohistochemistry when
HMGA2 nuclear immunoreactivity was detected in more than 20% of the cells in the
exocrine region.
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tion of rat thyroid cells in vitro (Berlingieri et al, 1995). The
interaction between HMGA2 and the AP-1 transcriptional complex
is considered to be responsible for the activation of genes whose
expressions are associated with carcinogenesis (Vallone et al,
1997), since thyroid neoplastic transformation is associated with a
drastic increase in AP-1 activity. This AP-1 activity is blocked by
suppressing HMGA protein synthesis in vitro (Battista et al, 1998).
The absence or decreased AP-1 transcriptional activity, which is
directly or indirectly regulated by HMGA proteins, would inhibit
the expression of AP-1-dependent genes, such as those of vascular
endothelial growth factor (VEGF), collagenase I (matrix metallo-
proteinase-1; MMP-1), and stromelisin (MMP-3), which are
essential for neoplastic transformation of cells (Vallone et al,
1997). In fact, significant downregulations of these mRNA
expression levels were demonstrated in the retrovirally infected
thyroid cell lines expressing the antisense HMGA2 (Vallone et al,
1997). Considering that the overexpression of the AP-1 (Tessari
et al, 1999; Meggiato et al, 2003), VEGF (Seo et al, 2000), MMP-1
(Ito et al, 1999), and MMP-3 (Bramhall et al, 1996) has been
demonstrated in human pancreatic cancer, together with our
results, the interactions among these molecules may play an
important role in pancreatic neoplastic transformation in vivo,
Further studies, including the determination of expression levels of
these molecules in tissue samples, have yet to be carried out to
further clarify this issue. Conversely, the HMGA2 gene has recently
been shown not to be necessary for the malignant transformation
of thyroid cells in vivo (Scala et al, 2001). This was demonstrated
by comparing the frequency of radiation or papilloma virus E7
gene-induced thyroid carcinomas in mice carrying disrupted
HMGA2 (pygmy mice) and that in mice carrying wild-type
HMGA2 (Scala et al, 2001). Pygmy mice developed thyroid
carcinomas with the same frequency as wild-type mice and
furthermore, these two carcinomas generated in different mice
showed no significant macroscopic and microscopic differences,
indicating that HMGA2 is not sufficient for in vivo malignant
transformation of thyroid cells (Scala et al, 2001). Several
hypotheses could be considered to explain the discrepancy with
the previous in vitro data, showing that HMGA2 is required for v-
mos- and v-ras-Ki-induced cell transformations. One possible
explanation would be that HMGA1, rather than HMGA2, may be
required for thyroid cell transformation. This hypothesis is
supported by the evidence that adenovirus carrying the HMGA1
gene in an antisense orientation induces programmed cell death in
carcinoma cell lines derived from human thyroid, lung, colon, and
breast cancers (Scala et al, 2000). We previously demonstrated that
human pancreatic carcinoma expresses high HMGA1 levels (Abe
et al, 2000, 2002), indicating that both HMGA2 and HMGA1 are
overexpressed in this lesion. The expression of only one of the
HMGA genes may be sufficient to lead epithelial cells of the
pancreatic duct to exhibit the malignant phenotype. Further
studies, such as the generation of HMGA1-knockout mice and
Figure 2 Immunohistochemical demonstration of the HMGA2 protein expression in pancreatic cancer cell lines. (A) AsPC-1 (Mayer’s haematoxylin;
original magnification  200). (B) PANC-I (Mayer’s haematoxylin; original magnification  200). (C) MIA PaCa-2 (Mayer’s haematoxylin; original
magnification  100). (D) BxPC-3 (Mayer’s haematoxylin; original magnification  200). Intense multifocal or diffuse HMGA2 nuclear immunoreactivity
(brown colour) was characteristically observed in cancer cells.
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nancies, need to be carried out in order to clarify the role of a
single HMGA gene in carcinogenesis in a wide variety of epithelial
tissues.
In conclusion, this study has clearly demonstrated that an
increased expression level of the HMGA2 gene/protein is closely
associated with the malignant phenotype in pancreatic exocrine
tissue, suggesting that HMGA2 could play a vital role in
Figure 3 Immunohistochemical demonstration of the HMGA2 protein expression in surgically resected specimens of non-neoplastic pancreatic tissues
and pancreatic carcinomas. (A) Non-neoplastic epithelial cells of the main pancreatic duct. A small proportion of duct epithelial cells show HMGA2
immunoreactivity (arrows). (Mayer’s haematoxylin; original magnification  200). (B) Epithelial cells of branch pancreatic duct and islets in chronic
pancreatitis tissue. Islet cells showed intense and diffuse HMGA2 immunoreactivity (arrows), while epithelial cells of the branch pancreatic duct did not
exhibit any detectable HMGA2 immunoreactivity (arrowhead) (Mayer’s haematoxylin; original magnification  100). (C) Primary pancreatic carcinoma
exhibiting well-differentiated tubular adenocarcinoma (Mayer’s haematoxylin; original magnification  200). (D) Primary pancreatic carcinoma exhibiting
adenosquamous carcinoma (Mayer’s haematoxylin; original magnification  200). (E) Metastatic lesion in the liver (Mayer’s haematoxylin; original
magnification  200). Intense and multifocal or diffuse HMGA2 immunoreactivity was noted in all the pancreatic carcinomas (C–E). (F) Section including
both carcinoma cells and islet cells (Mayer’s haematoxylin; original magnification  200). Islet cells showed intense and diffuse HMGA2 immunoreactivity
(arrows), which was almost equivalent to that observed in carcinoma cells (arrowheads).
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ytumorigenesis in the pancreatic exocrine system. The strong
correlation between HMGA2 overexpression and the histological
diagnosis of carcinoma indicates that the determination of the
expression level of HMGA2 can be of great value in the diagnosis
of pancreatic neoplasms.
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